BackPyxis Oncology Overview
Pyxis Oncology Inc

Pyxis Oncology Target Price

See Pyxis Oncology's analyst price targets ($7) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$3.89

Average Target Price

$7.0079.9% upside

1 analysts in the last 4 months

High: $7 | Low: $7

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-07-02Leerink PartnersJeffrey La Rosa$779.9% upsideOpen
2026-05-05WedbushRobert Driscoll$654.2% upsideOpen
2025-12-18RBC CapitalLeonid Timashev$528.5% upsideOpen
2025-11-24StephensSudan Loganathan$8105.7% upsideOpen
2025-11-04GuggenheimBradley Canino$779.9% upsideOpen
2025-09-04Guggenheim$528.5% upsideOpen
2024-08-16H.C. WainwrightSwayampakula Ramakanth$779.9% upsideOpen
2024-08-07Stifel NicolausBradley Canino$10157.1% upsideOpen
2024-05-07JefferiesFarzin Haque$10157.1% upsideOpen

Pyxis Oncology (PYXS) FAQ

Pyxis Oncology (PYXS) currently reports a target price of $7. Use the charts on this page to explore Pyxis Oncology's target price history and peer comparisons.

Analysts' average 12-month price target for Pyxis Oncology is $7, about 79.9% upside from the current share price of $3.89. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $7, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Pyxis Oncology, and consider following PYXS for alerts when major investors trade the stock.

Pyxis Oncology is classified in the Healthcare sector. On target price, it currently shows $7. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PYXS with unrelated industries.